levodopa has been researched along with Day Blindness in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alvino, FG; Carboncino, A; De Falco, S; De Leonibus, E; De Risi, M; Esposito, F; Franco, B; Indrieri, A; Marrocco, E; Tarallo, V | 1 |
| Cova, I; Priori, A | 1 |
| Atashzar, SF; Bernardinis, M; Jog, M; Patel, RV | 1 |
| Rosania, K | 1 |
| Amalric, M; De Leonibus, E; Giordani, F; Lopez, S; Managò, F; Mele, A; Oliverio, A; Petrosino, F | 1 |
| Acaroglu, G; Eryilmaz, T; Simsek, T | 1 |
| Bernauer, E; Finsterer, J | 1 |
| Gould, TJ; Johnson, LN; Krohel, GB | 1 |
| Guy, ME; Johnson, LN; Krohel, GB; Madsen, RW | 1 |
| Cox, TA | 1 |
| Hayreh, SS | 1 |
| Beck, RW | 1 |
| Duvoisin, RC | 1 |
| Bodis-Wollner, I; Onofrj, M | 1 |
| Ferrari, E | 1 |
1 review(s) available for levodopa and Day Blindness
| Article | Year |
|---|---|
Diagnostic biomarkers for Parkinson's disease at a glance: where are we?
Topics: alpha-Synuclein; Biomarkers; Brain; Cognition Disorders; Constipation; Depression; Early Diagnosis; Genetic Predisposition to Disease; Humans; Inflammation; Levodopa; Metabolomics; Microbiota; Movement Disorders; Neuroimaging; Olfaction Disorders; Parkinson Disease; REM Sleep Behavior Disorder; Symptom Assessment; Vision Disorders | 2018 |
3 trial(s) available for levodopa and Day Blindness
| Article | Year |
|---|---|
Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Optic Neuropathy, Ischemic; Prospective Studies; Treatment Outcome; Vision Disorders; Visual Acuity | 2005 |
Effect of levodopa and carbidopa on recovery of visual function in patients with nonarteritic anterior ischemic optic neuropathy of longer than six months' duration.
Topics: Aged; Aged, 80 and over; Arteritis; Carbidopa; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Optic Neuropathy, Ischemic; Pilot Projects; Prospective Studies; Vision Disorders; Visual Acuity | 1996 |
Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy.
Topics: Aged; Arteritis; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Optic Neuropathy, Ischemic; Time Factors; Vision Disorders; Visual Acuity; Visual Fields | 2000 |
11 other study(ies) available for levodopa and Day Blindness
| Article | Year |
|---|---|
α-synuclein overexpression in the retina leads to vision impairment and degeneration of dopaminergic amacrine cells.
Topics: alpha-Synuclein; Amacrine Cells; Animals; Dopaminergic Neurons; Female; Fluorescent Antibody Technique; Levodopa; Male; Mice; Mice, Inbred C57BL; Retina; Retinal Degeneration; Vision Disorders; Visual Acuity | 2020 |
Visual Displacement Perception in Parkinson's Disease Analyzed Using a Computer-Generated Graphical Tool.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Computers; Humans; Levodopa; Middle Aged; Parkinson Disease; Vision Disorders; Vision Tests; Vision, Ocular; Visual Perception | 2018 |
Parkinson's drug could treat diabetic retinopathy.
Topics: Animals; Antiparkinson Agents; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Levodopa; Mice; Rats; Vision Disorders | 2014 |
Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.
Topics: Animals; Association Learning; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Memory Disorders; Mice; Movement; Oxidopamine; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Space Perception; Vision Disorders | 2009 |
Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy.
Topics: Anti-Bacterial Agents; Antiparkinson Agents; Benzothiazoles; Brain; Chronic Disease; Dipeptides; Evoked Potentials, Visual; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Paromomycin; Pramipexole; Recovery of Function; Thiazoles; Treatment Outcome; Vision Disorders | 2005 |
Does levodopa improve visual function in NAION?
Topics: Arteritis; Dopamine Agents; Humans; Levodopa; Optic Neuropathy, Ischemic; Vision Disorders; Visual Acuity | 2000 |
Does Levodopa improve visual function in NAION?
Topics: Arteritis; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Optic Neuropathy, Ischemic; Research Design; Vision Disorders; Visual Acuity | 2000 |
Does Levodopa improve visual function in NAION?
Topics: Arteritis; Clinical Trials as Topic; Data Interpretation, Statistical; Dopamine Agents; Humans; Levodopa; Optic Neuropathy, Ischemic; Vision Disorders; Visual Acuity | 2000 |
Problems in the treatment of Parkinsonism.
Topics: Antiparkinson Agents; Arteriosclerosis; Carbidopa; Diagnosis, Differential; Drug Combinations; Eye Manifestations; Humans; Levodopa; Mental Disorders; Movement Disorders; Parasympatholytics; Paresthesia; Parkinson Disease; Vision Disorders | 1977 |
The visual system in Parkinson's disease.
Topics: Animals; Carbidopa; Drug Therapy, Combination; Evoked Potentials, Visual; Haplorhini; Humans; Levodopa; Parkinson Disease; Rats; Reaction Time; Vision Disorders; Vision Tests; Visual Acuity | 1987 |
[Problems in the administration of L-DOPA (author's transl)].
Topics: Cardiovascular Diseases; Drug Eruptions; Gastrointestinal Diseases; Humans; Levodopa; Mental Disorders; Movement Disorders; Parkinson Disease; Urologic Diseases; Vision Disorders | 1974 |